Africa Leads New TB Vaccine Trial That Could Save Millions

When Sibongile Hlatshwayo started coughing up blood, her family rushed her to a clinic in Johannesburg. Doctors eventually found what was wrong: tuberculosis, a disease that still kills more people worldwide than any other infection.

Her story isn't unusual. In 2024 alone, 10.7 million people fell ill with TB, and 1.23 million died from it.

But something remarkable is happening in the fight against this ancient killer. African scientists are now leading the charge with innovations that could finally turn the tide.

Dr. Lee Fairlie, a pediatrician and researcher at the University of Witwatersrand in Johannesburg, is heading one of the most promising TB vaccine trials in history. The M72 vaccine is being tested across Africa and Indonesia, and if successful, it will be the first TB vaccine to protect teenagers and adults in over 100 years.

The current vaccine, developed in the early 20th century, only protects young children. Its effectiveness fades as they grow older, leaving billions vulnerable.

What makes this moment different isn't just the science. For decades, clinical trials in Africa were run by institutions from outside the continent, with local communities serving as research sites but not decision makers.

That's changed. Today, African scientists across South Africa, Kenya, Malawi, and Zambia are designing, leading, and guiding TB research on their own terms.

The vaccine trial is just one piece of a bigger transformation. New diagnostic tools now use simple tongue swabs instead of complex lab samples, making testing faster and more accessible in remote areas. The World Health Organization recently gave these portable tests a strong recommendation.

Treatment is getting easier too. Most TB patients currently take multiple antibiotics for four to six months, even after feeling better. A new drug called sorfequiline showed promising results in early trials and could cut treatment time significantly, with larger studies expected to begin this year.

In South Africa, where more than 56,000 people die annually from TB, these advances carry special weight. The disease hits hardest in communities already dealing with HIV, making prevention and treatment even more urgent.

Community members like Fanyana Ngubane are ensuring the research stays connected to the people it aims to help. As chairperson of a Community Advisory Board, he bridges the gap between scientists and the neighborhoods where trials happen.

The Ripple Effect

No single breakthrough will end TB. But together, better vaccines, faster tests, shorter treatments, and stronger health systems are building momentum that experts haven't seen in generations.

The innovations emerging from African labs aren't just helping one continent. They're creating tools that will protect vulnerable people everywhere, led by scientists who understand the disease's impact firsthand.

For survivors like Hlatshwayo, who lived through months of grueling treatment, this progress means fewer families will face what hers did. The road ahead is long, but it's finally pointing toward a world where TB becomes rare instead of routine.